-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Institutional Owners May Take Dramatic Actions as Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Recent 20% Drop Adds to One-year Losses
Institutional Owners May Take Dramatic Actions as Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Recent 20% Drop Adds to One-year Losses
To get a sense of who is truly in control of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), it is important to understand the ownership structure of the business. With 84% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
And institutional investors saw their holdings value drop by 20% last week. The recent loss, which adds to a one-year loss of 64% for stockholders, may not sit well with this group of investors. Often called "market makers", institutions wield significant power in influencing the price dynamics of any stock. As a result, if the decline continues, institutional investors may be pressured to sell Rigel Pharmaceuticals which might hurt individual investors.
Let's take a closer look to see what the different types of shareholders can tell us about Rigel Pharmaceuticals.
See our latest analysis for Rigel Pharmaceuticals
NasdaqGS:RIGL Ownership Breakdown August 31st 2022What Does The Institutional Ownership Tell Us About Rigel Pharmaceuticals?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
As you can see, institutional investors have a fair amount of stake in Rigel Pharmaceuticals. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Rigel Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.
NasdaqGS:RIGL Earnings and Revenue Growth August 31st 2022Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. Rigel Pharmaceuticals is not owned by hedge funds. FMR LLC is currently the largest shareholder, with 14% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 14% and 9.5%, of the shares outstanding, respectively. In addition, we found that Raul Rodriguez, the CEO has 0.7% of the shares allocated to their name.
On further inspection, we found that more than half the company's shares are owned by the top 7 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
Insider Ownership Of Rigel Pharmaceuticals
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Our most recent data indicates that insiders own less than 1% of Rigel Pharmaceuticals, Inc.. It has a market capitalization of just US$239m, and the board has only US$1.8m worth of shares in their own names. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a 15% stake in Rigel Pharmaceuticals. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Rigel Pharmaceuticals better, we need to consider many other factors. For instance, we've identified 3 warning signs for Rigel Pharmaceuticals (2 are concerning) that you should be aware of.
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
為了弄清誰真正控制了裏格爾製藥公司(納斯達克代碼:RIGL),瞭解企業的所有權結構是很重要的。機構持有該公司84%的股份,擁有該公司的最高股份。換句話説,該集團將從他們對公司的投資中獲得最大(或損失最大)。
上週,機構投資者的持股價值下降了20%。最近的虧損加上股東一年來64%的虧損,可能會讓這羣投資者感到不快。機構通常被稱為“做市商”,在影響任何股票的價格動態方面擁有巨大的影響力。因此,如果跌勢持續,機構投資者可能會被迫出售Rigel PharmPharmticals,這可能會損害個人投資者的利益。
讓我們仔細看看不同類型的股東能告訴我們關於瑞格爾製藥的什麼。
查看我們對瑞格爾製藥公司的最新分析
NasdaqGS:RIGL所有權明細2022年8月31日機構所有權告訴了我們關於瑞格爾製藥公司的什麼?
機構投資者通常將自己的回報與經常跟蹤的指數的回報進行比較。因此,他們通常確實會考慮收購被納入相關基準指數的較大公司。
正如你所看到的,機構投資者在Rigel PharmPharmticals擁有相當數量的股份。這意味着為這些機構工作的分析師已經看過了這隻股票,他們喜歡它。但就像其他人一樣,他們也可能錯了。如果兩個大型機構投資者試圖同時拋售一隻股票,股價大幅下跌的情況並不少見。因此,值得查看一下瑞格爾製藥過去的盈利軌跡(見下圖)。當然,請記住,還有其他因素需要考慮。
NasdaqGS:RIGL收益和收入增長2022年8月31日由於機構投資者擁有一半以上的已發行股票,董事會可能不得不關注他們的偏好。Rigel PharmPharmticals不為對衝基金所有。FMR LLC目前是最大的股東,擁有14%的流通股。與此同時,第二大和第三大股東分別持有流通股的14%和9.5%。此外,我們還發現,首席執行官勞爾·羅德里格斯有0.7%的股份分配給了他們的名字。
進一步調查後,我們發現該公司超過一半的股份由前7名股東持有,這表明較大股東的利益在一定程度上被較小股東平衡了。
雖然研究一家公司的機構所有權數據是有意義的,但研究分析師的情緒以瞭解風向也是有意義的。有很多分析師在追蹤這隻股票,所以他們的預測可能也是值得的。
瑞格爾製藥的內部人所有權
公司內部人的定義可能是主觀的,而且在不同的司法管轄區之間確實有所不同。我們的數據反映了個別內部人士,至少捕捉到了董事會成員。公司管理層對董事會負責,董事會應代表股東的利益。值得注意的是,有時最高層管理人員本身也是董事會成員。
內部人持股是積極的,當它標誌着領導層像公司的真正所有者一樣思考時。然而,高內部人持股也可以給公司內部的一個小團體帶來巨大的權力。在某些情況下,這可能是負面的。
我們的最新數據顯示,內部人士持有Rigel PharmPharmticals,Inc.的股份不到1%。它的市值只有2.39億美元,董事會自己名下只有180萬美元的股票。許多小公司的投資者更希望看到董事會加大投資。你可以點擊這裏,看看這些內部人士是一直在買入還是賣出。
一般公有制
公眾通常是個人投資者,他們持有Rigel製藥公司15%的股份。儘管這種規模的所有權可能不足以影響有利於他們的政策決定,但他們仍然可以對公司政策產生集體影響。
接下來的步驟:
擁有一家公司股票的不同集團總是值得考慮的。但為了更好地瞭解瑞格爾製藥,我們還需要考慮許多其他因素。例如,我們已經確定Rigel製藥公司的3個警告標誌(2)你應該知道的。
最終未來是最重要的。您可以訪問此免費分析師對該公司的預測報告。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧